阿里:把「AI+雲」為核心科技業務打造成第二增長曲線
阿里巴巴-SW(09988.HK)(BABA.US)發布2025財年年報,在年報致股東信中,董事長蔡崇信和吳泳銘表示,全球AI技術浪潮帶來的全新時代正在開啟。展望未來,阿里必須抱著從零開始的心態,像創業公司一樣思考和行動,才能捕捉機遇及創造機遇。阿里的基因裏沒有守成,只有創造。今天的阿里巴巴,正在以創業者的姿態,開啟面向AI時代的全新征程。
信中表示,未來十年,最大的增量和變數都是以AI為核心的驅動力帶來的變革。AI時代的阿里巴巴,在市場上處於絕佳的戰略地位,在內地雲計算市場佔據重要身位。有信心依靠阿里的人才、技術與資源,將把握住發展機遇,把「AI+雲」為核心的科技業務打造成阿里的第二增長曲線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.